Hire an Advanced Robo-Advisor to Trade AMGN on Your Behalf.
- Street Sentiment
- Personalized Strategy
- Free Trading Simulator
Course of Action
Sentiment (10 days)
- Strong Buy
- Strong Sell
DAILY PRICE CHANGE VS SENTIMENT
Why Invest Using a Robo-Trader?
Smart Auto-Trading is an advanced Robo-Trader designed to automate securities investing. Its robo is designed to screens, monitors and auto-trades elite stocks like AMGEN INC. (AMGN) using Artificial Intelligence, social media and market data. Using Smart Auto-Trading in your brokerage account holds the potential to accelerate your financial performance.
Converting your 401k to a Rollover IRA and auto-trade in it using Smart Auto-Trading from Stock Circles could be a great strategy to grow your retirement account while you work. Smart Auto-Trading is an actively trading robo-trader that auto-trades the S&P 500 on your behalf.
Based on historical performance, Smart Auto-Trading's model strategies have have yielded more than twice the S&P. It holds the potential to grow retirement accounts quicker than passive investment vehicles using the same securities. Active trading is a systematic investment strategy that uses price momentum, short-term trades and compounding to build wealth.
In the past 2 years, the system has produced great results. Smart Auto-Trading makes short-term trades. If these trades happen in a tax-deferred account, you do not get taxed until you start taking money out of the account. So if you start auto-trading today in your retirement account and auto-trade for 10, 20, 30 years, imagine how much money this automated strategy as the potential to create for you.
This investment system works great for tax-deferred accounts like Keogh, SIMPLE IRA, traditional IRA, IRA, Rollover IRA, 529 College plans and UGMA and you can trade with a minimum of $25,000 in your account.
Smart Auto-Trading is very affordable. You will pay a low monthly fee to use it. Using Smart Auto-Trading will usually pay for itself on the first successful trade of the month.
Robo investing is super easy
Robo-investing with Smart Auto-Trading is easy. You do not need to know anything about stock investing. All you need to do is to setup your trading strategy and the trading robot will take care of the rest. Stock Circles offers a default strategy to help you get started. You can test the strategy in simulation mode free of charge today. Once comfortable with the outcome, you are ready to trade real money. You can then connect Smart Auto-Trading to your brokerage account and start to auto-trade.
Past performance does not guarantee future success. Smart Auto-Trading will do its best to take advantage of the market but if the market goes down for a long period of time then there is no money to be made than everyone is affected. Robo-Traders like Smart Auto-Trading are good at what they do but they don’t have super powers.
Smart Auto-Trading trades only elite stocks. By trading the S&P 500, Nasdaq 100 and Dow 30, Smart Auto-Trading uses widely traded stocks.
Smart Auto-Trading uses Artificial Intelligence concepts to screen, monitor and auto-trade stocks. It monitors and trades on your behalf while you attend more important life events.
Take advantage of active trading today by registering at stockcircles.com It's free to start in simulation mode.
There are clear benefits associated with using a robo-Traders such as Smart Auto-Trading to help you reach your financial goals. Smart Auto-Trading simplifies stock investing down to a few steps. It auto-trades for you, using your personalized strategy, while you attend more important life events.
Using Smart Auto-Trading is like having thousands of traders working for you to help you reach your financial goals.
Smart Auto-Trading actively trades which is different from passive investing. The robo is on the lookout working to maximize your potential every business day of the year. It trades on the news taking advantage of price changes and trends by listening into trader's communications and by validating this information with market data.
Smart Auto-Trading is one of the first Robo-Trader to take advantage of Government grade listening technology, Artificial Intelligence, social media and market data natively.
Try Smart Auto-Trading today!
You can test Smart Auto-Trading in simulation mode, risk free, Stock Circles today.
Disclaimer: Past performance may not be indicative of future results. Therefore, you should assume that the future performance of any specific investment, investment strategy (including robo-strategies), or product made in reference directly or indirectly on this website, will be profitable or equal to corresponding indicated performance levels. Robot-Traders like other investment methods rely on favorable market conditions to provide positive outcomes.
AMGEN INC. (AMGN) News
Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS® (carfilzomib) Label
Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a label variation for KYPROLIS® (carfilzomib) to include the final overall survival (OS) data from the Phase 3 ASPIRE trial. The ASPIRE trial demonstrated that the addition of KYPROLIS to lenalidomide and dexamethasone (KRd) reduced the risk of death by 21 percent versus lenalidomide and dexamethasone alone (Rd) and extended OS by 7.9 months in patients with relapsed or refractory multiple myeloma (median OS 48.3 months for KRd versus 40.4 months for Rd, HR = 0.79, 95 percent CI, 0.67 – 0.95; 1-sided p=0.0045).
"This latest positive CHMP opinion marks the second time Amgen will add overall survival data from a Phase 3 study to the label, further validating the fundamental role of KYPROLIS in treating patients with relapsed or refractory multiple myeloma," said David M. Reese, M.D., senior vice president of Translational Sciences and Oncology at Amgen. "This is a major step towards advancing KYPROLIS-based regimens as standard of care, and we look forward to the European Commission's decision later this year."
KYPROLIS is approved in the European Union (EU) for use in combination with lenalidomide and dexamethasone or with dexamethasone alone (Kd) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Kd regimen of twice-weekly KYPROLIS administered at 56 mg/m2 and the KRd regimen of twice-weekly KYPROLIS administered at 27 mg/m2 are the first and only therapeutic combinations to demonstrate consistently improved OS versus recent standards of care in two Phase 3 trials in relapsed or refractory multiple myeloma patients (Kd versus bortezomib and dexamethasone [Vd] and KRd versus Rd).
Since its approval in 2012, approximately 80,000 patients worldwide have received KYPROLIS. The KYPROLIS clinical program continues to focus on providing treatment options for physicians and patients for this frequently relapsing and difficult-to-treat cancer.Get Started today! - Risk Free